Journal of Clinical Oncology
Articles in this Issue
Neoadjuvant low-dose carboplatin and docetaxel in combination with toripalimab for early or locally advanced triple-negative breast cancer (NeoTOP): A single-arm phase 2 trial.
589 Background: Neoadjuvant immunotherapy combined with chemotherapy improves the rate of pathological complete response (pCR) and prognosis of triple-neg...
Clinicopathologic features and outcomes of follicular dendritic cell sarcoma with or without Castleman disease: A large retrospective cohort analysis.
11549 Background: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm with a subset associated with unicentric Castleman disease (UCD). However, t...
NSCLC in the immunotherapy era: Trends in survival and disparities across demographic and socioeconomic groups.
e20565 Background: Advanced non-small cell lung cancer (NSCLC) has historically been associated with poor survival outcome...
Comprehensive clinical and genomic characterization of advanced urachal and non-urachal adenocarcinomas of the urinary tract.
e16618 Background: Adenocarcinomas of the urinary tract, including urachal (UA) and non-urachal (NUA) subtypes, are rare tumors lacking standard systemic...
Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease.
7082 Background: Idiopathic multicentric Castleman disease (iMCD) is a hematologic disorder treated by oncologists and characterized by diffuse lymphadeno...
Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer: Analysis of toxicity and cosmetic outcomes.
514 Background: Locoregional management of early stage breast cancer (BC) has evolved from maximal tolerable to minimal effective therapies. Significant a...
Community opinion leaders and traditional healers’ perceptions and experiences on the need for breast and cervical cancer screening in Nigeria: A qualitative study.
e23227 Background: Early Breast Cancer (BC) and Cervical Cancer (CC) screening have proven to be important secondary prevention strategies in reducing mor...
Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
4556 Background: The IMDC risk model is pivotal for predicting clinical outcomes in pts with mRCC, yet variability exists within the IR group. Moreover, t...
Efficacy of long-course versus short-course chemoradiotherapy combined with immunotherapy for pMMR/MSS rectal adenocarcinoma: A real-world cohort study.
e15645 Background: The integration of immunotherapy with chemoradiotherapy (CRT) represents a novel therapeutic strategy for pMMR/MSS rectal adenocarcinom...
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.
515 Background: Dalp, a potent CDK4/6 inhibitor, has demonstrated significant improvements in PFS when combined with ET in both first-line and later-line...
Financial toxicity and drivers of delayed care among cancer survivors across the lifespan.
1521 Background: Financial toxicity has been increasingly recognized as a cause of poor outcomes among cancer survivors. Cancer survivors have been shown...
Prognostic significance of HER2 heterogeneity in early-stage and locally advanced HER2-positive breast cancer.
e12595 Background: Breast cancer tumors often have intratumoral heterogeneity (ITH), which has been associated with therapeutic resistance. Tumors with hi...
Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI).
7558 Background: In our Institution, a prospective study to test the combination of gene-expression-profiling (SKY92 gene signature) and new generation im...
Assessing the role of cytarabine-based regimens in mantle cell lymphoma: A real world study.
7058 Background: Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma. For decades, cytarabine-based regimens have been the corners...
Dynamics of the tumor marker (TM) cancer antigen 15.3 (CA 15.3) and its association with overall survival (OS) in patients (pts) with hormone-receptor (HR)-positive/HER2-negative advanced breast cancer (ABC) in a public oncologic institution of Peru.
e13080 Background: CA 15.3 is a conventional TM commonly elevated in HR (+) /HER2 (-) ABC at diagnosis and is associated with a high burden of disease and...
Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial.
2523 Background: The most common type of cutaneous T-cell lymphoma is Mycosis Fungoides (MF) accounting for 50-60% of cases. Extracutaneous involvement oc...
Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
5091 Background: CHAARTED criteria using CT and bone scan are widely recognized as prognostic in metastatic, hormone-sensitive prostate cancer (mHSPC) and...
Facilitating meaningful patient involvement in the design and conduct of cancer research: The Breast International Group (BIG) patient partnership model.
e23009 Background: BIG is a global network of > 50 academic research groups conducting large multinational breast cancer (BC) trials. BIG has worked wi...
Atrial fibrillation epidemiology and impact on clinical outcomes in non-Hodgkin lymphoma patients hospitalized with sepsis: Evidence from nationwide data.
e19048 Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is frequently complicated by sepsis. There is an association between...
Optimizing biomarker testing and targeted therapy integration in early-stage NSCLC: A quality improvement initiative at community oncology clinics.
e23223 Background: Treatments for early-stage non-small cell lung cancer (NSCLC) are rapidly evolving, with biomarker testing as a cornerstone of treatmen...
Association of court-documented major adverse financial events before cancer diagnosis and mortality risk in the US.
1519 Background: Cancer diagnosis is associated with increased risk of financial hardship in the US. This study examined the associations of court-documen...
Insights into the mortality trends due to gastric cancer across 204 regions worldwide: 1990 to 2021.
e16118 Background: Gastric cancer continues to affect public health worldwide because it causes high death rates and disability numbers. Despite advanceme...
The role of income and rurality in US cancer mortality: A SEER analysis.
e13828 Background: Disparities in cancer outcomes between rural and urban populations are often linked to limited healthcare resources in rural areas. How...
Evaluation of a 1021-gene NGS panel for HRD detection in clinical samples.
e17569 Background: Molecular profiling of tumors using Next Generation Sequencing (NGS) enables the detection of genetic alterations associated with respo...
The potential of disitamab vedotin in bladder preservation during neoadjuvant therapy for bladder cancer: A comparative analysis with the GC regimen.
e16585 Background: The goal of neoadjuvant therapy for bladder cancer is to improve pathological outcomes and provide patients with the opportunity to pre...